Literature DB >> 9762921

NMDA-receptor antagonist requirements in conantokin-G.

T Blandl1, M Prorok, F J Castellino.   

Abstract

A series of variants of the neuroactive 17-residue gamma-carboxyglutamate-(Gla)-containing polypeptide, conantokin-G (con-G), were synthesized with the intention of determining those features that were important for its N-methyl-D-aspartate (NMDA) receptor-targeted antagonist activity and for adoption of its divalent cation-dependent alpha-helical conformation. Employing the binding of [3H]dizolcipine (MK-801) as an assay for open receptor ion channels in rat brain membranes, which displays inhibition by con-G (IC50 = 0.48 microM), it was found that replacement by an Ala residue of Gla4 led to complete inactivation of the peptide, whereas a similar replacement of Gla3 resulted in a 20-fold decreased potency. Ala substitutions for Gla10 and Gla14 did not substantially affect [3H]MK-801 binding. This same substitution at Gla7 appeared to slightly enhance binding. Ala replacements of non-Gla residues demonstrated that four of them, viz. Glu2, Leu5, Gln9, and Ile12, possessed at least 200-fold decreases in inhibitory potency, whereas similar replacements at Gly1, Leu11, and Arg13 resulted in peptides with 8- to 12-fold increases in the IC50 values. The remaining amino acid residues tested in the single Ala replacement series showed no significant changes in the inhibitory characteristics of wild-type con-G. Additional studies with carboxyl-terminal truncated peptides revealed that the carboxyl-terminal 4 amino acids were unimportant for this activity. There was no strict correlation of inhibition of [3H]MK-801 binding with the ability of these peptides to form cation-dependent alpha-helices. Peptides with notably low alpha-helical content in the presence of these cations were lacking at least one, or both, of Gla10 and Gla14. Con-G[Gla3,4,7,10,14E] and con-G[Gla7,10,14E] were the only peptides that remained in a completely random conformation upon metal ion addition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9762921     DOI: 10.1016/s0014-5793(98)01077-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

1.  Hydroxyproline-induced Helical Disruption in Conantokin Rl-B Affects Subunit-selective Antagonistic Activities toward Ion Channels of N-Methyl-d-aspartate Receptors.

Authors:  Shailaja Kunda; Yue Yuan; Rashna D Balsara; Jaroslav Zajicek; Francis J Castellino
Journal:  J Biol Chem       Date:  2015-06-05       Impact factor: 5.157

2.  From molecular phylogeny towards differentiating pharmacology for NMDA receptor subtypes.

Authors:  Randall J Platt; Kigen J Curtice; Vernon D Twede; Maren Watkins; Paweł Gruszczyński; Grzegorz Bulaj; Martin P Horvath; Baldomero M Olivera
Journal:  Toxicon       Date:  2014-02-07       Impact factor: 3.033

3.  Characterization of conantokin Rl-A: molecular phylogeny as structure/function study.

Authors:  Konkallu H Gowd; Maren Watkins; Vernon D Twede; Grzegorz W Bulaj; Baldomero M Olivera
Journal:  J Pept Sci       Date:  2010-08       Impact factor: 1.905

4.  Stapling mimics noncovalent interactions of γ-carboxyglutamates in conantokins, peptidic antagonists of N-methyl-D-aspartic acid receptors.

Authors:  Randall J Platt; Tiffany S Han; Brad R Green; Misty D Smith; Jack Skalicky; Pawel Gruszczynski; H Steve White; Baldomero Olivera; Grzegorz Bulaj; Joanna Gajewiak
Journal:  J Biol Chem       Date:  2012-04-19       Impact factor: 5.157

5.  NR2B-selective conantokin peptide inhibitors of the NMDA receptor display enhanced antinociceptive properties compared to non-selective conantokins.

Authors:  Cai Xiao; Yuanyuan Huang; Mingxin Dong; Jie Hu; Shuangshuang Hou; Francis J Castellino; Mary Prorok; Qiuyun Dai
Journal:  Neuropeptides       Date:  2008-11-07       Impact factor: 3.286

Review 6.  Neuroprotective and cardioprotective conopeptides: an emerging class of drug leads.

Authors:  Vernon D Twede; George Miljanich; Baldomero M Olivera; Grzegorz Bulaj
Journal:  Curr Opin Drug Discov Devel       Date:  2009-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.